GreenLight Biosciences Acquires Bayer's topical RNA Intellectual Property portfolio
News provided by
Share this article
Share this article
BOSTON, May 20, 2021 /PRNewswire/ -- GreenLight Biosciences today announced that they have acquired rights to portions of Bayer's topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.
The RNA-based Varroa mite control advance allows beekeepers to directly target the Varroa mite without harming the honeybee, a critical advantage to other treatments on the market today.
Honeybee with parasitic Varroa destructor mite
RNA's potential for improving plant, animal, and human health has been known for years, but widespread commercial use hasn't previously been possible, due to RNA's cost of production and slow production time.